©The Author(s) 2022.
World J Hepatol. Feb 27, 2022; 14(2): 429-441
Published online Feb 27, 2022. doi: 10.4254/wjh.v14.i2.429
Published online Feb 27, 2022. doi: 10.4254/wjh.v14.i2.429
Table 2 Univariate and multivariate analysis for predictors of diminished β-Arrestin-2 expression after nonselective β-blockers
| Parameters | Univariate analysis | Multivariate analysis | |||
| P value | OR | P value | OR | 95%CI | |
| ALT | 0.51 | - | - | - | - |
| AST | 0.20 | - | - | - | - |
| Platelets | 0.26 | - | - | - | - |
| APRI | 0.06 | - | - | - | - |
| Albumen | 0.25 | - | - | - | - |
| Bilirubin | 0.69 | - | - | - | - |
| Child-Turcotte-Pugh class | 0.73 | - | - | - | - |
| Baseline EV grade | 0.003 | 1.35 | - | - | - |
| Baseline β-Arr-2 expression | < 0.001 | 2.41 | - | - | - |
| NSBB dose | 0.049 | 6.5 | 0.02 | 1.01 | 0.91-1.05 |
| ΔPVCI | < 0.001 | 10.34 | 0.005 | 1.58 | 0.001- 0.002 |
- Citation: Lashen SA, Shamseya MM, Madkour MA, Abdel Salam RM, Mostafa SS. β-arrestin-2 predicts the clinical response to β-blockers in cirrhotic portal hypertension patients: A prospective study. World J Hepatol 2022; 14(2): 429-441
- URL: https://www.wjgnet.com/1948-5182/full/v14/i2/429.htm
- DOI: https://dx.doi.org/10.4254/wjh.v14.i2.429